康健國際醫療(3886.HK)2021年度溢利達7,507萬港元 成功化危為機、實現由虧轉盈
康健國際醫療(3886.HK)公佈2021年度業績,期內集團實現收入14.8億港元,同比增長38.8%;溢利為7,507萬港元,上年同期為虧損2.6億港元;公司擁有人應占溢利為2,201萬港元,上年同期為虧損2.8億港元;每股基本盈利為0.29港仙,宣派末期股息每股0.15港仙。
公吿稱,集團收入增長主要歸因於2021年(I)香港醫療服務;(II)內地醫院管理及相關服務;及(III)2019冠狀病毒病檢測服務的需求增加。業績扭虧為盈主要歸因於(I)各主要業務板塊於2021年錄得收入、利潤增長;(II)於2021年錄得投資物業之公平值收益,而上一年度為虧損;(III)於2021年錄得應占聯營公司溢利增長;及(IV)於2021年相關資產確認之預期信貸虧損及減值虧損減少。
香港業務方面,年內本地疫情緩和、經濟保持向好勢頭、醫療需求顯著改善及保健情緒升温等利好因素,孵化集團年前所進行的業務佈局、營運策略及開源節流措施。年內,集團醫療服務業務表現拾級向上,醫療網絡管理業務穩健增長、自營連鎖醫務中心業務走出疫情陰霾,疊加病毒核酸檢測服務的需求增加,致使業績表現大幅改善。
內地業務方面,內地疫情調控得當,宏觀經濟政策靈活精準,內地經濟實現穩步復甦。集團在總體經濟保持增長的動能下,把握醫療市場發展方向、挖掘健康保健機遇,不斷強化醫院管理及健康管理業務的競爭力和多元性,深化與中國人壽集團的合作,鋭意爭取拓展企業客户,推動整體業務於年內錄得穩健增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.